Cecilia A. C. Prinsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cecilia A. C. Prinsen has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Barbara Terwee
Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands
6 shared publications - Christian Apfelbacher
Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke University Magdeburg, Magdeburg, Germany
3 shared publications - Lidwine Brigitta Mokkink
Department of Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
3 shared publications Caroline B. Terwee
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Boelelaan 1117, Amsterdam, The Netherlands
2 shared publications- Daniel Heinl
Medical Sociology, Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany
2 shared publications - Michael R. Rose
Department of Neurology, King's College Hospital, London, UK
2 shared publications
Latest Publications
- Open Access
- 9 October 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-11
Core outcome domain sets for clinical trials in epidermolysis bullosa — a COSEB protocol to achieve consensus on “what” to measure
Background: Epidermolysis bullosa (EB) comprises a heterogeneous group of rare, genetic blistering diseases. The wide variety in EB trial outcomes limits the comparability of outcomes and, consequently, the implementation of the best available treatment options. A core outcome set (COS) is a minimum set of outcomes that should be measured in all clinical trials, comprising what should be measured (i.e., outcome domains) and how it should be measured (i.e., outcome measurement instruments). This enables standardization of outcome measurement aiming at improving the comparability and quality of research. Methods: The Core Outcome Set for Epidermolysis Bullosa (COSEB) initiative aims to develop COSs for use in clinical trials for the four major EB types: EB simplex, junctional EB, dystrophic EB, and Kindler EB. This protocol focuses on the development of core outcome domain sets — outlining what should be measured in EB clinical trials. Involved stakeholders are patients and patient representatives, clinicians, researchers, methodologists, industry representatives, regulators, health technology assessors, and payers. In the initial part, working groups are formed to define long lists of candidate outcome domains for the four major EB types. Potentially relevant outcome domains will be identified based on scoping literature reviews and qualitative studies. Following consultations with a stakeholder advisory panel, a short list of candidate outcome domains will be subject to voting in Delphi consensus procedures. Finally, the definitive core outcome domain sets for the four major EB types and, if indicated, any overarching core outcome domain sets, will be confirmed in consensus meetings. The project Has been prospectively registered in the COMET registry for COSs on 23 October 2017 (registration number 1033). Discussion: This protocol provides guidance to ensure a systematic, transparent, and comprehensible approach of COSEB. The final core outcome domain sets are supposed to serve as the minimum sets of what to measure in future EB trials. This will provide the basis for the subsequent outcome measurement instrument selection. Particularly in this rare disease with inherently small-sized study cohorts, this will facilitate the incorporation of meaningful outcomes and pooling of data, ultimately enhancing optimal treatment for EB. Trial registration: This study Has been prospectively registered in the COMET database on 23 October 2017 and updated on 24 January 2022 (registration number 1033 https://www.comet-initiative.org/studies/details/1033).
- 9 October 2025
- Published by Springer Nature in Trials
- Vol. 26 (1) , 1-11
Open AccessCore outcome domain sets for clinical trials in epidermolysis bullosa — a COSEB protocol to achieve consensus on “what” to measure
Background: Epidermolysis bullosa (EB) comprises a heterogeneous group of rare, genetic blistering diseases. The wide variety in EB trial outcomes limits the comparability of outcomes and, consequently, the implementation of the best available treatment options. A core outcome set (COS) is a minimum set of outcomes that should be measured in all clinical trials, comprising what should be measured (i.e., outcome domains) and how it should be measured (i.e., outcome measurement instruments). This enables standardization of outcome measurement aiming at improving the comparability and quality of research. Methods: The Core Outcome Set for Epidermolysis Bullosa (COSEB) initiative aims to develop COSs for use in clinical trials for the four major EB types: EB simplex, junctional EB, dystrophic EB, and Kindler EB. This protocol focuses on the development of core outcome domain sets — outlining what should be measured in EB clinical trials. Involved stakeholders are patients and patient representatives, clinicians, researchers, methodologists, industry representatives, regulators, health technology assessors, and payers. In the initial part, working groups are formed to define long lists of candidate outcome domains for the four major EB types. Potentially relevant outcome domains will be identified based on scoping literature reviews and qualitative studies. Following consultations with a stakeholder advisory panel, a short list of candidate outcome domains will be subject to voting in Delphi consensus procedures. Finally, the definitive core outcome domain sets for the four major EB types and, if indicated, any overarching core outcome domain sets, will be confirmed in consensus meetings. The project Has been prospectively registered in the COMET registry for COSs on 23 October 2017 (registration number 1033). Discussion: This protocol provides guidance to ensure a systematic, transparent, and comprehensible approach of COSEB. The final core outcome domain sets are supposed to serve as the minimum sets of what to measure in future EB trials. This will provide the basis for the subsequent outcome measurement instrument selection. Particularly in this rare disease with inherently small-sized study cohorts, this will facilitate the incorporation of meaningful outcomes and pooling of data, ultimately enhancing optimal treatment for EB. Trial registration: This study Has been prospectively registered in the COMET database on 23 October 2017 and updated on 24 January 2022 (registration number 1033 https://www.comet-initiative.org/studies/details/1033).
- Open Access
- 11 July 2022
- Published by Springer Nature in Current Diabetes Reports
- Vol. 22 (9) , 405-421
Content Validity of Patient-Reported Outcome Measures Developed for Assessing Health-Related Quality of Life in People with Type 2 Diabetes Mellitus: a Systematic Review
Purpose of review: We aimed to systematically evaluate the content validity of patient-reported outcome measures (PROMs) specifically developed to measure (aspects of) health-related quality of life (HRQOL) in people with type 2 diabetes. A systematic review was performed in PubMed and Embase of PROMs measuring perceived symptoms, physical function, mental function, social function/participation, and general health perceptions, and that were validated to at least some extent. Content validity (relevance, comprehensiveness, and comprehensibility) was evaluated using COSMIN methodology. Recent findings: We identified 54 (different versions of) PROMs, containing 150 subscales. We found evidence for sufficient content validity for only 41/150 (27%) (subscales of) PROMs. The quality of evidence was generally very low. We found 66 out of 150 (44%) (subscales of) PROMs with evidence for either insufficient relevance, insufficient comprehensiveness, or insufficient comprehensibility. For measuring diabetes-specific symptoms, physical function, mental function, social function/participation, and general health perceptions, we identified one to 11 (subscales of) PROMs with sufficient content validity, although quality of the evidence was generally low. For measuring depressive symptoms, no PROM with sufficient content validity was identified. Summary: For each aspect of HRQL, we found at least one PROM with sufficient content validity, except for depressive symptoms. The quality of the evidence was mostly very low.
- 11 July 2022
- Published by Springer Nature in Current Diabetes Reports
- Vol. 22 (9) , 405-421
Open AccessContent Validity of Patient-Reported Outcome Measures Developed for Assessing Health-Related Quality of Life in People with Type 2 Diabetes Mellitus: a Systematic Review
Purpose of review: We aimed to systematically evaluate the content validity of patient-reported outcome measures (PROMs) specifically developed to measure (aspects of) health-related quality of life (HRQOL) in people with type 2 diabetes. A systematic review was performed in PubMed and Embase of PROMs measuring perceived symptoms, physical function, mental function, social function/participation, and general health perceptions, and that were validated to at least some extent. Content validity (relevance, comprehensiveness, and comprehensibility) was evaluated using COSMIN methodology. Recent findings: We identified 54 (different versions of) PROMs, containing 150 subscales. We found evidence for sufficient content validity for only 41/150 (27%) (subscales of) PROMs. The quality of evidence was generally very low. We found 66 out of 150 (44%) (subscales of) PROMs with evidence for either insufficient relevance, insufficient comprehensiveness, or insufficient comprehensibility. For measuring diabetes-specific symptoms, physical function, mental function, social function/participation, and general health perceptions, we identified one to 11 (subscales of) PROMs with sufficient content validity, although quality of the evidence was generally low. For measuring depressive symptoms, no PROM with sufficient content validity was identified. Summary: For each aspect of HRQL, we found at least one PROM with sufficient content validity, except for depressive symptoms. The quality of the evidence was mostly very low.
- Open Access
- 9 August 2019
- Published by Springer Nature in Systematic Reviews
- Vol. 8 (1) , 1-9
Performance properties of health-related measurement instruments in whiplash: systematic review protocol
Whiplash is a common traumatic cervical injury which is most often a consequence of rear-end motor vehicle accidents. It has been estimated that up to 50% of the whiplash patients suffer from chronic symptoms, resulting in extensive individual and societal burden. Several measurement instruments are used for initial assessment of whiplash and evaluation of response to treatment. However, a comprehensive assessment of the performance of these measures is lacking. Furthermore, there is no consensus on the most relevant outcome domains and their corresponding measurement instruments of choice. This systematic review aims to identify, describe, and critically appraise the performance properties of health-related measurement instruments in whiplash population. The following literature databases will be searched from their date of establishment: PubMed, Embase®, MEDLINE, CINAHL Complete, PsycINFO, and HAPI. All original articles evaluating the reliability, validity, responsiveness, and feasibility of health-related measurement instruments in whiplash will be included, without additional restriction on their intended use, source of data, and structure. Risk of bias will be assessed using the COSMIN Risk of Bias checklist. Findings of the studies will be judged against the criteria for good measurement properties, and results from all studies will be qualitatively summarized to generate an overall quality of findings. Overall quality of evidence will be determined using a modified GRADE approach, which will be used in conjunction with the overall quality of results for generation of recommendations. Two reviewers will perform all steps of the review independently. Discrepancies will be discussed between the reviewers, and in case of remaining disagreement, the senior reviewer will make the final decision. This systematic review will summarize the body of literature on health-related measurement instruments in whiplash, aiming to facilitate the selection of high-quality measurement instrument for researchers and physicians. Findings of this study will guide the ongoing efforts for development of a core outcome set. PROSPERO reference number CRD42018070901
- 9 August 2019
- Published by Springer Nature in Systematic Reviews
- Vol. 8 (1) , 1-9
Open AccessPerformance properties of health-related measurement instruments in whiplash: systematic review protocol
Whiplash is a common traumatic cervical injury which is most often a consequence of rear-end motor vehicle accidents. It has been estimated that up to 50% of the whiplash patients suffer from chronic symptoms, resulting in extensive individual and societal burden. Several measurement instruments are used for initial assessment of whiplash and evaluation of response to treatment. However, a comprehensive assessment of the performance of these measures is lacking. Furthermore, there is no consensus on the most relevant outcome domains and their corresponding measurement instruments of choice. This systematic review aims to identify, describe, and critically appraise the performance properties of health-related measurement instruments in whiplash population. The following literature databases will be searched from their date of establishment: PubMed, Embase®, MEDLINE, CINAHL Complete, PsycINFO, and HAPI. All original articles evaluating the reliability, validity, responsiveness, and feasibility of health-related measurement instruments in whiplash will be included, without additional restriction on their intended use, source of data, and structure. Risk of bias will be assessed using the COSMIN Risk of Bias checklist. Findings of the studies will be judged against the criteria for good measurement properties, and results from all studies will be qualitatively summarized to generate an overall quality of findings. Overall quality of evidence will be determined using a modified GRADE approach, which will be used in conjunction with the overall quality of results for generation of recommendations. Two reviewers will perform all steps of the review independently. Discrepancies will be discussed between the reviewers, and in case of remaining disagreement, the senior reviewer will make the final decision. This systematic review will summarize the body of literature on health-related measurement instruments in whiplash, aiming to facilitate the selection of high-quality measurement instrument for researchers and physicians. Findings of this study will guide the ongoing efforts for development of a core outcome set. PROSPERO reference number CRD42018070901
- 1 May 2019
- Published by Elsevier in Public Health
- Vol. 170, 70-77
Measuring positive health: for now, a bridge too far
- 1 May 2019
- Published by Elsevier in Public Health
- Vol. 170, 70-77
Measuring positive health: for now, a bridge too far
- Open Access
- 29 March 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (3) , 579-580
By using a core outcome set we measure what matters to patients
- 29 March 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (3) , 579-580
Open AccessBy using a core outcome set we measure what matters to patients
- Top Cited PapersOpen Access
- 12 February 2018
- Published by Springer Nature in Quality of Life Research
- Vol. 27 (5) , 1147-1157
COSMIN guideline for systematic reviews of patient-reported outcome measures
Systematic reviews of patient-reported outcome measures (PROMs) differ from reviews of interventions and diagnostic test accuracy studies and are complex. In fact, conducting a review of one or more PROMs comprises of multiple reviews (i.e., one review for each measurement property of each PROM). In the absence of guidance specifically designed for reviews on measurement properties, our aim was to develop a guideline for conducting systematic reviews of PROMs.
- 12 February 2018
- Published by Springer Nature in Quality of Life Research
- Vol. 27 (5) , 1147-1157
Top Cited PapersOpen AccessCOSMIN guideline for systematic reviews of patient-reported outcome measures
Systematic reviews of patient-reported outcome measures (PROMs) differ from reviews of interventions and diagnostic test accuracy studies and are complex. In fact, conducting a review of one or more PROMs comprises of multiple reviews (i.e., one review for each measurement property of each PROM). In the absence of guidance specifically designed for reviews on measurement properties, our aim was to develop a guideline for conducting systematic reviews of PROMs.
- 22 January 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (1) , 23-25
T‐QoL: a quality of life outcome measure specifically developed for adolescents with skin diseases
- 22 January 2018
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (1) , 23-25
T‐QoL: a quality of life outcome measure specifically developed for adolescents with skin diseases
- 22 September 2017
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 177 (3) , 616-617
Changing patients’ understanding of psoriasis is promising
- 22 September 2017
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 177 (3) , 616-617
Changing patients’ understanding of psoriasis is promising
- 24 October 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (3) , 424-431
Why quality of life measurement is important in dermatology clinical practice
The aim of this study was to describe the many ways in which quality of life (QoL) measurement may potentially be advantageous in routine clinical dermatology practice. Thirteen members of the EADV Task Force on Quality of Life, eight dermatologists, three health psychologists, one epidemiologist and one pharmacoepidemiologist, independently listed all of the ways they thought this may be advantageous. A total of 108 different ways of using QoL information in clinical practice were suggested (median per participant = 8, range = 4–15), and were classified into 20 descriptive groups. These were sorted into the following five categories: inform clinical decisions, clinician–patient communication, awareness of skin disease burden, informing the consultation and clinical service administration. The wide range of potential benefits identified may not only encourage clinicians to use these measures but also highlights many areas requiring evidence to establish the true value of routine use of QoL measures.
- 24 October 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (3) , 424-431
Why quality of life measurement is important in dermatology clinical practice
The aim of this study was to describe the many ways in which quality of life (QoL) measurement may potentially be advantageous in routine clinical dermatology practice. Thirteen members of the EADV Task Force on Quality of Life, eight dermatologists, three health psychologists, one epidemiologist and one pharmacoepidemiologist, independently listed all of the ways they thought this may be advantageous. A total of 108 different ways of using QoL information in clinical practice were suggested (median per participant = 8, range = 4–15), and were classified into 20 descriptive groups. These were sorted into the following five categories: inform clinical decisions, clinician–patient communication, awareness of skin disease burden, informing the consultation and clinical service administration. The wide range of potential benefits identified may not only encourage clinicians to use these measures but also highlights many areas requiring evidence to establish the true value of routine use of QoL measures.
- Top Cited PapersOpen Access
- 13 September 2016
- Published by Springer Nature in Trials
- Vol. 17 (1) , 1-10
How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” – a practical guideline
In cooperation with the Core Outcome Measures in Effectiveness Trials (COMET) initiative, the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) initiative aimed to develop a guideline on how to select outcome measurement instruments for outcomes (i.e., constructs or domains) included in a “Core Outcome Set” (COS). A COS is an agreed minimum set of outcomes that should be measured and reported in all clinical trials of a specific disease or trial population. Informed by a literature review to identify potentially relevant tasks on outcome measurement instrument selection, a Delphi study was performed among a panel of international experts, representing diverse stakeholders. In three consecutive rounds, panelists were asked to rate the importance of different tasks in the selection of outcome measurement instruments, to justify their choices, and to add other relevant tasks. Consensus was defined as being achieved when 70 % or more of the panelists agreed and when fewer than 15 % of the panelists disagreed. Of the 481 invited experts, 120 agreed to participate of whom 95 (79 %) completed the first Delphi questionnaire. We reached consensus on four main steps in the selection of outcome measurement instruments for COS: Step 1, conceptual considerations; Step 2, finding existing outcome measurement instruments, by means of a systematic review and/or a literature search; Step 3, quality assessment of outcome measurement instruments, by means of the evaluation of the measurement properties and feasibility aspects of outcome measurement instruments; and Step 4, generic recommendations on the selection of outcome measurement instruments for outcomes included in a COS (consensus ranged from 70 to 99 %). This study resulted in a consensus-based guideline on the methods for selecting outcome measurement instruments for outcomes included in a COS. This guideline can be used by COS developers in defining how to measure core outcomes.
- 13 September 2016
- Published by Springer Nature in Trials
- Vol. 17 (1) , 1-10
Top Cited PapersOpen AccessHow to select outcome measurement instruments for outcomes included in a “Core Outcome Set” – a practical guideline
In cooperation with the Core Outcome Measures in Effectiveness Trials (COMET) initiative, the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) initiative aimed to develop a guideline on how to select outcome measurement instruments for outcomes (i.e., constructs or domains) included in a “Core Outcome Set” (COS). A COS is an agreed minimum set of outcomes that should be measured and reported in all clinical trials of a specific disease or trial population. Informed by a literature review to identify potentially relevant tasks on outcome measurement instrument selection, a Delphi study was performed among a panel of international experts, representing diverse stakeholders. In three consecutive rounds, panelists were asked to rate the importance of different tasks in the selection of outcome measurement instruments, to justify their choices, and to add other relevant tasks. Consensus was defined as being achieved when 70 % or more of the panelists agreed and when fewer than 15 % of the panelists disagreed. Of the 481 invited experts, 120 agreed to participate of whom 95 (79 %) completed the first Delphi questionnaire. We reached consensus on four main steps in the selection of outcome measurement instruments for COS: Step 1, conceptual considerations; Step 2, finding existing outcome measurement instruments, by means of a systematic review and/or a literature search; Step 3, quality assessment of outcome measurement instruments, by means of the evaluation of the measurement properties and feasibility aspects of outcome measurement instruments; and Step 4, generic recommendations on the selection of outcome measurement instruments for outcomes included in a COS (consensus ranged from 70 to 99 %). This study resulted in a consensus-based guideline on the methods for selecting outcome measurement instruments for outcomes included in a COS. This guideline can be used by COS developers in defining how to measure core outcomes.